- Home
- FPF vs PCRX Comparison
FPF vs PCRX Comparison
Compare FPF & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPF
- PCRX
- Stock Information
- Founded
- FPF 2013
- PCRX 2006
- Country
- FPF United States
- PCRX United States
- Employees
- FPF N/A
- PCRX 790
- Industry
- FPF Trusts Except Educational Religious and Charitable
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- FPF Finance
- PCRX Health Care
- Exchange
- FPF Nasdaq
- PCRX Nasdaq
- Market Cap
- FPF 1.2B
- PCRX 1.2B
- IPO Year
- FPF N/A
- PCRX 2011
- Fundamental
- Price
- FPF $19.20
- PCRX $26.45
- Analyst Decision
- FPF
- PCRX Buy
- Analyst Count
- FPF 0
- PCRX 6
- Target Price
- FPF N/A
- PCRX $30.00
- AVG Volume (30 Days)
- FPF 186.7K
- PCRX 666.0K
- Earning Date
- FPF 01-01-0001
- PCRX 08-05-2025
- Dividend Yield
- FPF 8.08%
- PCRX N/A
- EPS Growth
- FPF N/A
- PCRX N/A
- EPS
- FPF N/A
- PCRX N/A
- Revenue
- FPF N/A
- PCRX $705,848,000.00
- Revenue This Year
- FPF N/A
- PCRX $7.36
- Revenue Next Year
- FPF N/A
- PCRX $10.07
- P/E Ratio
- FPF N/A
- PCRX N/A
- Revenue Growth
- FPF N/A
- PCRX 2.25
- 52 Week Low
- FPF $13.91
- PCRX $12.61
- 52 Week High
- FPF $18.09
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- FPF 60.51
- PCRX 61.33
- Support Level
- FPF $19.01
- PCRX $25.14
- Resistance Level
- FPF $19.32
- PCRX $27.04
- Average True Range (ATR)
- FPF 0.12
- PCRX 0.82
- MACD
- FPF -0.01
- PCRX 0.07
- Stochastic Oscillator
- FPF 72.34
- PCRX 69.49
About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.